Updating results

401 results

Sort: Relevance | Date

Specialist neonatal respiratory care for babies born preterm

In development [GID-QS10137] Expected publication date: 20 March 2020

Quality standard In development

Renal and ureteric stones

In development [GID-QS10095] Expected publication date: 16 April 2020

Quality standard In development

Cerebral palsy in adults

In development [GID-QS10080] Expected publication date: 23 January 2020

Quality standard In development

Rheumatoid arthritis in over 16s (QS update)

In development [GID-QS10136] Expected publication date: 09 January 2020

Quality standard In development

Faltering growth

In development [GID-QS10083] Expected publication date: 02 June 2020

Quality standard In development

Decision-making and mental capacity

In development [GID-QS10127] Expected publication date: 31 March 2020

Quality standard In development

Abortion care

In development [GID-QS10084] Expected publication date: 18 August 2020

Quality standard In development

Workplace health: long-term sickness absence and management

In development [GID-QS10114] Expected publication date: 13 January 2021

Quality standard In development

Community pharmacies: promoting health and wellbeing

In development [GID-QS10115] Expected publication date: 02 June 2020

Quality standard In development

Elective joint replacement

In development [GID-QS10090] Expected publication date: 13 January 2021

Quality standard In development

Carers: provision of support for adult carers

In development [GID-QS10128] Expected publication date: 04 December 2020

Quality standard In development

Heavy menstrual bleeding (QS update)

In development [GID-QS10134] Expected publication date: 23 June 2020

Quality standard In development

Fetal alcohol spectrum disorder

In development [GID-QS10139] Expected publication date: 31 July 2020

Quality standard In development

Lung cancer (update)

In development [GID-QS10132] Expected publication date: 13 December 2019

Quality standard In development

Suspected neurological conditions

In development [GID-QS10082] Expected publication date: 03 July 2020

Quality standard In development

Flu vaccination: increasing uptake

In development [GID-QS10071] Expected publication date: 09 January 2020

Quality standard In development

School-based interventions: physical and mental health and wellbeing promotion

In development [GID-QS10070] Expected publication date: TBC

Quality standard In development

Maternal health

In development [GID-QS10077] Expected publication date: TBC

Quality standard In development

Intrapartum care: existing medical conditions or obstetric complications

In development [GID-QS10081] Expected publication date: 04 February 2020

Quality standard In development

Indoor air quality at home

In development [GID-QS10113] Expected publication date: 20 October 2020

Quality standard In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 11 December 2019

Technology appraisal guidance In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Technology appraisal guidance In development

Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: TBC

Technology appraisal guidance In development

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: 16 December 2020

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: TBC

Technology appraisal guidance In development

Liraglutide for managing overweight and obesity [ID740]

In development [GID-TA10388] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [ID1521]

In development [GID-TA10471] Expected publication date: TBC

Technology appraisal guidance In development

Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583]

In development [GID-TA10530] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

In development [GID-TA10429] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1584]

In development [GID-TA10533] Expected publication date: 24 June 2020

Technology appraisal guidance In development

Zynteglo for treating transfusion-dependent beta-thalassaemia ID968

In development [GID-TA10334] Expected publication date: 24 June 2020

Technology appraisal guidance In development

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]

In development [GID-TA10529] Expected publication date: TBC

Technology appraisal guidance In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

In development [GID-TA10510] Expected publication date: TBC

Technology appraisal guidance In development

Acalabrutinib for treating chronic lymphocytic leukaemia ID1613

In development [GID-TA10532] Expected publication date: TBC

Technology appraisal guidance In development

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [ID1576]

In development [GID-TA10463] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

In development [GID-TA10459] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for treating interstitial lung disease caused by systemic sclerosis (ID1420)

In development [GID-TA10427] Expected publication date: TBC

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development